MDWD MEDIWOUND LTD
Permanent stock page ↗Health Care · Russell 2000
Next earnings: Thu 12 Nov 2026 · before market open
What 8 analyst firms say about MEDIWOUND LTD: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 8 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8069
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8044
Recent analyst activity · last 90 days
Our tracked history has 5 reports on MDWD from 5 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it, 1 left it unchanged and 2 have their first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Oppenheimer lowered its target from $32.00 (set 28 May 2026) to $30.00 on 14 Aug 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Alliance Global Partners | Scott R Henry | Buy | 16 Sep 2026 | 27.00 USD |
| Craig-Hallum | Chase Knickerbocker | Buy | 27 May 2026 | 36.00 USD |
| H.C. Wainwright | Swayampakula Ramakanth | Buy | 14 Aug 2026 | 36.00 USD |
| Maxim Group | Michael Okunewitch | Buy | 15 Mar 2026 | 30.00 USD |
| Oppenheimer | Francois Brisebois | Buy | 14 Aug 2026 | 30.00 USD |
| TD Cowen | Joshua T Jennings | Buy | 24 Sep 2026 | 25.00 USD |
| Weiss Ratings | Unnamed analyst | — | 8 Sep 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 07:39 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.